Chardan Capital Maintains Buy on Senti Biosciences, Raises Price Target to $12

Benzinga Newsdesk www.benzinga.com Positive 90.0%

Neg 0% Neu 0% Pos 90%

Chardan Capital analyst Geulah Livshits maintains Senti Biosciences (NASDAQ:SNTI) with a Buy and raises the price target from $11 to $12.